Eli Lilly (NYSE: LLY) was an unstoppable bet in the past few years, but LLY stock finally started plateauing in the latter ...

US drug prices are up to five times higher than in other developed nations. Trump's order requires US drug prices to align ...

A bold move by US President Donald Trump to slash the cost of prescription drugs in America has sent shockwaves through the ...

Eli Lilly’s expanding US production and advancing pipeline offset near-term headwinds and support bullish conviction. Read ...

GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock ...

U.S.-listed shares of Novo Nordisk plunged 7% in intraday trading Thursday after rival Eli Lilly reported positive oral weight-loss drug news and BMO cut its rating for the Danish drug developer's ...

Analysts are still crunching the numbers on the impact of President Donald Trump's executive order from Monday on drug pricing. HSBC analyst Rajesh Kumar says a 20% price cut in government channels ...

Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of ...

Over the last couple of years, one of the best pharma stocks to own has been Eli Lilly ( LLY -3.19%). But now, an investment in Lilly may not look so enticing as the possibility of more tariffs loom.

From late 2020 to the summer of 2024, Eli Lilly ... in share price, however, investor sentiment for the next line of drugs front ran the stock price. For example, in 2016 Lilly was trading ...

Eli Lilly and Company's stock dropped 11% after CVS's Zepbound exclusion, but analysts see a mispricing opportunity. Click for why LLY growth remains strong.

Eli Lilly on Thursday posted better-than-expected quarterly results, but CVS Health's decision to drop the company's obesity ...